Jong Woo Lee
Epilepsy · Newton, MANPI 1376640094
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by SK Life Science, Inc. at 54.1% of the total. Reporting peaked in 2022 at $3,168 and has fallen 91.0% since, to $286 in 2025.
Across 17 payments — averaging $420.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$4K
- Biogen$3K
- UCB, Inc.$83
- Straumann USA LLC$50
- Bayer$23
- Catalyst Pharmaceuticals, Inc.$17
Across 12 payments — averaging $7166.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$86K
What the payments were for
- Consulting fees$3,10843%
- Speaking & faculty fees$3,00042%
- Food & beverage$97814%
- Education$671%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 11 | $3,873 |
| Biogen | 1 | $3,108 |
| UCB, Inc. | 2 | $83 |
| Straumann USA LLC | 1 | $50 |
| Bayer | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$125
How this compares
$7,152 in reported general payments places this provider in the 75th percentile of 28 epilepsy providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 207 | $397,171 |
| EpidiolexCannabidiol (Cbd) | 34 | $193,932 |
| AptiomEslicarbazepine Acetate | 45 | $133,811 |
| BriviactBrivaracetam | 57 | $115,350 |
| FycompaPerampanel | 54 | $70,857 |
| LamictalLamotrigine | 17 | $60,151 |
| Lamictal XrLamotrigine | 17 | $46,570 |
| NayzilamMidazolam | 21 | $45,053 |
| Lamotrigine ErLamotrigine | 68 | $30,931 |
| Lacosamide | 132 | $21,939 |
| Clobazam | 103 | $15,603 |
| Levetiracetam ErLevetiracetam | 81 | $8,729 |
| DilantinPhenytoin Sodium Extended | 16 | $5,033 |
| Lamotrigine | 147 | $4,297 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $4,008 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $3,873 | $397,171207 claims |
| UCB, Inc.Briviact, Nayzilam | $83 | $160,40378 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 epilepsy providers in Massachusetts.
Other epilepsy in Newton
- Roberto CiordiaDorchester$186K
- Andrew ColeBoston$186K
- Claire JacobsBoston$118K
- Ioannis KarakisBoston$56K
- Milena PavlovaBoston$23K
- Alice LamBoston$10K
- Rani SarkisBoston$6K
- Paula VoinescuBoston$5K
- Kevin WuCambridge$1K
- Anthony TranMilton$633
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.